Clinical Trial: Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364474) titled 'Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver' on Dec. 16, 2025.

Brief Summary: This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) for patients with Uveal Melanoma that has metastasized to the liver.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Uveal Melanoma

Intervention: DRUG: Melphalan through Percutaneous Hepatic Perfusion

Melphalan through Percutaneous Hepatic Perfusion will be received as standard of care,

Recruitment Status: NOT_YET_R...